StockData

IDEXX Laboratories vs QuidelOrtho

IDXX and QDEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IDXX and QDEL compare

IDEXX Laboratories is the larger company, worth 80 times as much as QuidelOrtho ($54.4B against $677M).

IDEXX Laboratories grew revenue faster over the last twelve months (12.8% versus −4.5% for QuidelOrtho).

IDEXX Laboratories keeps more of each dollar of sales as profit, with a net margin of 25.0% compared with −14.2% at QuidelOrtho.

IDEXX Laboratories scores higher on the StockData Score (19 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIDXXQDEL
Size and price
Market cap$54.4B$677M
Share price$690.24$9.87
Change, 1 year0.04%−53.7%
Change, 5 years13.6%−93.2%
Beta (5Y)0.341.32
Employees11K6,500
StockData Score
Total score19 (better)6
Valuation score23 (better)
Growth score5 (better)0
Performance score6 (better)2
Health score6 (better)1
Dividend score00
Valuation
P/E48.5×–
P/S11.9×0.3× (better)
P/B33.7×0.4× (better)
EV/EBITDA33.9×10.3× (better)
P/FCF43.4×–
PEG2.75–
FCF yield2.3% (better)−17.3%
Fair value$509.32$26.64
Margin of safety−35.5%63.0% (better)
Growth
Revenue growth (TTM)12.8% (better)−4.5%
Revenue growth, 5Y average9.7%10.4% (better)
Net income growth (TTM)15.6%–
EPS growth (TTM)18.4%–
EPS growth, 5Y average14.3%–
Profitability
Gross margin62.4% (better)44.2%
Operating margin32.0% (better)−4.9%
Net margin25.0% (better)−14.2%
FCF margin27.5% (better)−4.5%
Return on equity74.2% (better)−19.3%
Return on invested capital63.3% (better)−2.2%
Financial health
Debt / equity0.28 (better)1.64
Net debt / EBITDA0.16 (better)8.29
Interest coverage38.6× (better)−0.6×
Current ratio1.171.36 (better)
Altman Z-score23.48 (better)0.26
Piotroski F-score8 (better)6
Dividends and buybacks
Buyback yield2.2% (better)−0.66%
Shareholder yield2.2% (better)−0.66%
Ownership
Held by institutions94.5%121%
Held by insiders0.29%43.4%
Insider net buying, 12 months−$58.4M$669K (better)
Superinvestors holding3–
Short interest, % of float3.0%37.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.